



From Bench to Bedside: Translational Breakthroughs in Castration-Resistant Prostate Cancer Research

Guest Editor:

Dr. Wanting Han

Pete Nelson Lab, Human Biology,
Fred Hutchinson Cancer Center,
Seattle, WA, USA

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Prostate cancer is the second most diagnosed malignancy and the fifth leading cause of cancer death among men globally, underscoring the urgent need for advanced therapeutic strategies.

This Special Issue will present cutting-edge translational research that bridges experimental science and clinical application, focusing on the persistent challenge of CRPC. Contributions should detail the progress in this field, from identifying molecular targets in the lab to developing novel therapies that enhance patients' quality of life and survival. We welcome submissions detailing innovative diagnostic approaches, targeted therapies, immunotherapies, antibody–drug conjugates (ADCs), and strategies for overcoming drug resistance.

Researchers are invited to share their findings on the biology of CRPC, particularly new insights into its development and progression, and the translation of these findings into clinical practice. This Special Issue aims to be a testament to the collaborative efforts of scientists and clinicians who are turning the tide against prostate cancer, offering hope through their commitment to research that culminates in saving lives.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)